Another hypothesis is that E*01:01 could more efficiently present EBV-derived peptides to CD8+ T lymphocytes than E*01:03, generating an increased cytotoxic T cell response to EBV infection. The gene discussed is CD8A; the disease is Epstein-Barr virus infection.